Filing Flows › Health Care › Idexx Laboratories (IDXX)
Idexx Laboratories (IDXX) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Nov 2, 2026 · Idexx Laboratories (IDXX) Q3 2026 earnings results →
Q3 2026 Revenue up 10% year over year to $1.2B · 26¢ of every $1 of revenue kept as net profit · operating margin 33.1%
Idexx Laboratories made $1.2B in Q3 2026 (+10% Y/Y): Product revenue $723M, Service revenue $491M. Operating margin 33.1%, net earnings $317M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 2, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $1.2B in Q3 2026, up 10% year over year and roughly flat from the previous quarter. Product revenue was the largest line at 60% of revenue. Product revenue added $0.07B year over year (up 10%), 61% of the total change.
Gross margin was 62.9%, up 1.1 points from Q3 2025. Operating profit was $0.40B, a 33.1% margin (up 1.0 points year over year). Of the extra revenue versus Q3 2025, 44% reached operating profit, above the 32% margin then. Operating expenses grew 10% against revenue growth of 10%. The fastest-growing cost line was General & admin (+16%). Net earnings were $0.32B, up 15% year over year. The effective tax rate was 20.6%.
Operating cash flow was $0.45B (up 12% year over year), 142% of net earnings. Non-cash charges added back $0.04B of depreciation and amortization and $0.02B of share-based compensation. Working capital and other items added $0.08B. Capital expenditures of $0.03B left free cash flow of $0.42B.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Nov 2, 2026 | $1.2B | +10% | 33.1% | $317M | $450M |
| Q2 2026 | 10-Q | Aug 4, 2026 | $1.2B | +10% | 35.0% | $338M | $347M |
| Q1 2026 | 10-Q | May 5, 2026 | $1.1B | +14% | 31.8% | $278M | $266M |
| Q4 2025 | 10-K | Feb 20, 2026 | $1.1B | +14% | 28.9% | $248M | $356M |
| Q3 2025 | 10-Q | Nov 3, 2025 | $1.1B | +13% | 32.1% | $275M | $402M |
| Q2 2025 | 10-Q | Aug 4, 2025 | $1.1B | +11% | 33.6% | $294M | $186M |
| Q1 2025 | 10-Q | May 1, 2025 | $998M | +4% | 31.7% | $243M | $238M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
Customers and suppliers named in filings
Buys from
About Idexx Laboratories
IDEXX was incorporated in Delaware in 1983. We develop, manufacture, and distribute products and provide services primarily for the companion animal veterinary; livestock, poultry and dairy; and water testing industries. We also manufacture and sell human medical point-of-care diagnostic products. Our primary products and services are: • Health monitoring, biological materials testing, laboratory diagnostic instruments, and services used by the biomedical research community;
In its own words, from its 10-K, filed Feb 20, 2026.
Idexx Laboratories against its In Vitro & In Vivo Diagnostic Substances peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +10% against the peers' median +2%. Operating margin: 33.1% against the peers' median -1.2%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| IDXX Idexx Laboratories | Q3 2026 | $1.2B | +10% | 33.1% |
| QDEL QuidelOrtho | Q3 2026 | $619M | -12% | -1.2% |
| LNTH Lantheus Holdings | Q3 2026 | $390M | +2% | 8.3% |
| NEOG Neogen | Q1 FY27 | $223M | +6% | -0.8% |
| MYGN Myriad Genetics | Q3 2026 | $203M | -2% | -19.7% |
| TKNO Alpha Teknova | Q3 2026 | $12.7M | +22% | -25.2% |
| ICCC Immucell | Q2 2026 | $7.2M | +12% | 26.9% |
| NTLA Intellia Therapeutics | Q3 2026 | $7.2M | -48% | n/m |
| AWHL Aspira Women's Health | Q2 2026 | $2.0M | -15% | -89.7% |
Source: Idexx Laboratories 10-Q on SEC EDGAR · CIK 874716 · In Vitro & In Vivo Diagnostic Substances
Guidance and outlook
13F: who owns IDXX and who is buying
More on IDXX
- How Idexx Laboratories makes money: revenue by segment
- Idexx Laboratories next earnings date and what analysts expect
- Idexx Laboratories stock forecast, price target and fair value
- Who owns Idexx Laboratories stock: holders, funds and Congress trades
- Idexx Laboratories guidance and outlook
- Is Idexx Laboratories a takeover target? LBO and rumors
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results
- Idexx Laboratories guidance history: guided vs reported
- Idexx Laboratories gross margin by quarter
- Idexx Laboratories operating margin by quarter
- Idexx Laboratories net income by quarter
- Idexx Laboratories free cash flow by quarter
- Idexx Laboratories R&D spending by quarter
- Idexx Laboratories capital expenditures by quarter
- Idexx Laboratories Product revenue revenue by quarter
- Idexx Laboratories Service revenue revenue by quarter